New Treatments for Systemic Lupus Erythematosus
Author Information
Author(s): Muacevic Alexander, Adler John R, Kaye Alan D, Tassin Joseph P, Upshaw William C, Patel Chandni R, Hawkins Alison M, Burroughs Caroline R, Bembenick Kristin Nicole, Mosieri Chizoba N, Ahmadzadeh Shahab, Kaye Adam M, Shekoohi Sahar, Varrassi Giustino
Primary Institution: Louisiana State University Health Sciences Center
Hypothesis
What are the evolving treatment strategies for systemic lupus erythematosus (SLE) in clinical practice?
Conclusion
New biologic agents and treatments show promise in managing systemic lupus erythematosus, but more research is needed to confirm their safety and efficacy.
Supporting Evidence
- Belimumab and anifrolumab have shown significant reductions in SLE symptoms in clinical trials.
- Patients treated with belimumab reported better quality of life and experienced fewer lupus flares.
- Anifrolumab trials demonstrated improvements in SLE manifestations compared to placebo.
Takeaway
Doctors are finding new ways to help people with lupus feel better, using special medicines that target the disease more effectively.
Methodology
The review discusses various treatments for SLE, including clinical trials of new biologic agents.
Limitations
The review highlights the need for more information regarding the safety and efficacy of new treatments.
Participant Demographics
The study involved individuals over the age of 18 with seropositive SLE.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website